students on campus



Profile for Min Kang, Pharm.D.

Min Kang

Min Kang, Pharm.D.

  • Associate Vice President of Research
  • Professor (Tenured), Department of Pediatrics, SOM Cancer Center
Mail Address: 3601 4th St Stop 9445
Lubbock TX 79430-9445

Biography

Min Hee Kang is currently a Distinguished University Professor of Pediatrics at the Texas Tech University Health Sciences Center School of Medicine. She earned her Bachelor in Pharmacy in South Korea in 1990, and her PharmD from the University of Colorado Health Sciences Center, Denver in 1998. After completing her PharmD, she joined the National Cancer Institute, National Institutes of Health as a post-doctoral fellow.
In 2005, Min accepted an assistant professor position at the University of Southern California-Children’s Hospital Los Angeles. Dr. Kang co-directed the National Cancer Institute Pediatric Preclinical Development Program in vitro testing laboratory for 10 years, and the data she generated resulted in numerous publications and several early-phase pediatric clinical trials.
Dr. Kang was recruited to TTUHSC as an assistant professor in 2008. She was promoted to an associate professor with tenure in 2011 and to professor in 2015. Dr. Kang’s research has been continuously funded by both the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health (NIH). Dr. Kang has received several recognitions for her research and teaching, including President’s Young Investigator award in 2010, President’s Excellence in Research Award in 2013, University Distinguished Faculty in 2015, and the Outstanding Faculty Award by TTUHSC Student Governance Association 2014 and 2015. She has authored over 100 peer-reviewed publications, and her H-index is 31. She serves as a reviewer on NIH Study Sections.

Positions:

  • Associate Vice President of Research, Texas Tech University Health Sciences Center 2018-Present
  • Professor (Tenured), Department of Pediatrics, SOM Cancer Center, Texas Tech University Health Sciences Center Lubbock, Texas 2015-Present
  • Associate Professor, Dept. of Cell Biology & Biochemistry and Dept. of Neuroscience & Pharmacology, TTUHSC SOM Lubbock, TX 2011-2015
  • Assistant Professor, Cell Biology & Biochemistry, Pharmacology & Neuroscience, Lubbock 2008-2015
  • Assistant Professor of Pediatrics , Keck School of Medicine, University of Southern California, Childrens Hospital Los Angeles, CA 2005-2008

Post Doctoral Education:

  • Post-Doctoral fellow: Chungbuk National University, South Korea , 2002
  • Post-doctoral fellow: National Cancer Institute, NIH, 2001

Education:

  • Pharm.D.: University of Colorado Health Sciences Center, 1998
  • MS: Chungbuk National University, School of Pharmacy, 1992
  • BS: Chungbuk National University, School of Pharmacy, 1990

Selected Publications:

  • Cho H, Kang MH. pH gradient-Liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells.. J of Chromatography 2018.
  • Cho HE, Kang MH. Analysis of Fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.. Journal of Pharmaceutical and Biomedical Analysis 2017;132:117-124.
  • Sheard MA, Ghent MV, Cabral DJ, Lee JC, Khankaldyyan V, Jia L, Wu SQ, Kang MH, Sposto R, Asgharzadeh S, Reynolds CP. Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.. Experimental Cell Research 2015;334(1):78-89.
  • Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.. Pediatric blood & cancer 2015;62(6):1106-9.
  • Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP. Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression.. Clinical cancer research: An official journal of the American Association for Cancer Research 2015;21(5):1139-50.
  • Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.. Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21(4):819-32.
  • Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.. Pediatric blood & cancer 2015;62(1):91-8.
  • Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.. British journal of pharmacology 2014;171(23):5330-44.
  • Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.. Pediatric blood & cancer 2014;61(11):1972-9.
  • Ryu Y, Hall CP, Reynolds CP, Kang MH. Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.. Experimental biology and medicine (Maywood, N.J.) 2014;239(10):1390-402.
  • Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.. Pediatric blood & cancer 2014;61(8):1486-9.
  • Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.. Pediatric blood & cancer 2014;61(8):1493-6.
  • Tagde A, Singh H, Kang MH, Reynolds CP. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.. Blood cancer journal 2014;4:e229.
  • Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.. Pediatric blood & cancer 2014;61(5):922-4.
  • Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.. BMC research notes 2014;7:256.

Selected Presentations:

  • Kang MH., The Japanese Society of Medical Oncology 2015 Annual Meeting, Japanese Society of Medical Oncology, Sapporo, Japan July 2015.
    Ketoconazole improved fenretinide exposures and achieved clinical responses in recurrent neuroblastoma: A NANT study
  • Kang MH., School of Medicine Seminar, Nagoya University, Nagoya, Japan July 2015.
    Enhancing drug activity of anti-neoplastic drugs with novel drug formulations.
  • Murphy B, Yin H, Maris JM, Kolb AE, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RM, Dvorchik I, Wu J, Billups C, Smith MA, Houghton PJ., Annual Meeting, American Association for Cancer Research (AACR), Philadelphia, Pennsylvania April 2015.
    Analysis of single mouse tumor response results from the Pediatric Preclinical Testing Program (PPTP).
  • Song MM, Makena MR, Hindle A, Koneru B, Nguyen TH, Cho H, Baurer BJ, Kang MH, Reynolds CP., Annual Meeting, American Association for Cancer Research (AACR), Philadelphia, Pennsylvania April 2015.
    Comparison of the cytotoxicity and increase of reactive oxygen species and dihydroceramides of fenretinide to its major metabolites (4-oxo- and 4-methoxyphenyl fenretinide) in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines.
  • Smith MA, Kang MH, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb AE, Maris JM, Keir ST, Billups CA, Kurmasheva R, Houghton PJ., Annual Meeting, American Association for Cancer Research (AACR), Philadelphia, Pennsylvania April 2015.
    Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP).
  • Kang MH., Four Diamonds Pediatric Cancer Research Series, Penn State University, Hershey, Pennsylvania April 2014.
    Optimizing drug therapy by pharmacokinetics and biomarkers in pediatric cancer
  • Kang MH., American Association for Cancer Research Annual Meeting, San Diego, California April 2014.
    Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression
  • Kang MH, Hall C., American Association for Cancer Research Annual Meeting, American Association for Cancer Research, San Diego, California April 2014.
    NVP-BEZX235 enhances dexamethasone-induced BIM expression and apoptosis in models of T-ALL with PTEN dysfunction and increased PI3K/AKT activity
  • Kang MH, Smith M, Reynolds C, Gorlick R, Kolb A, Maris J, Lock R, Carol H, ., American Association for Cancer Research Annual Meeting, American Association for Cancer Research, San Diego, California April 2014.
    Pediatric preclinical testing program (PPT) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temogolomide (TMZ)
  • Kang MH., 4. Rett Nearburg International Ewing’s Sarcoma Symposium, Nearburg Foundation, San Diego, CA November 2013.
    High activity of liposomal irinotecan (MM-398) in Ewings family tumor xenografts is associated with superior exposure of tumor to drug and high SLFN11 expression

Selected Contracts and Grants:

  • National Cancer Institute (NCI) - National Institutes of Health (NIH), R01CA232591
    2019-2023
    R01 MYC activation in tumor progression of neuroblastoma
    $1,890,722.00 [Total Cost]
    Principal Investigator
  • National Institutes of Health/National Cancer Institute (NIH/NCI), R01CA217251
    2018-2023
    Alternate telomere maintenance in high-risk neuroblastoma as prognostic indicators and therapeutic targets
    $1,749,940.00 [Total Cost]
    Co-Investigator
  • National Cancer Institute (NCI), 1R01 CA221957
    2018-2021
    Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines
    $1,650,000.00 [Total Cost]
    Co-Principal Investigator
  • Cancer Prevention and Research Institute of Texas (CPRIT), RP170470
    2016-2020
    OCT4/c-MYC axis as a mechanism of resistance to 13-cis retinoic acid in neuroblastoma
    $1,115,137.00 [Total Cost]
    Principal Investigator
  • Cancer Prevention and Research Institute of Texas (CPRIT), RP150416
    2015-2019
    Translational Investigations of fenretinide and safingol form pediatric cancer use
    $1,999,415.00 [Total Cost]
    Co-Investigator
  • National Cancer Institute (NCI), 1 R01 CA168699-01A1
    2013-2018
    Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in high-risk neuroblastoma
    $890,277.00 [Total Cost]
    Principal Investigator
  • National Cancer Institute (NCI) - National Institutes of Health (NIH)
    2011-2016
    Phase I trial of fenretinide + safingol
    $217,567.00 [Total Cost]
    Co-Investigator
  • Cancer Prevention Research Institute of Texas (CPRIT), RP130547
    2013-2016
    Pharmacokinetics and Pharmacogenomics of 13-cis-retinoic acid in treatment outcome of COG Phase III neuroblastoma trials
    $821,051.00 [Total Cost]
    Principal Investigator
  • NCI, HHSN261200422016C
    2004-2014
    Pediatric Preclinical Testing Program
    $543,605.00 [Total Cost]
    Co-Principal Investigator
  • NCI, 1R21CA161889
    2011-2014
    A Phase I trial combining fenretinide and safingol to target overproduction of dihydroceramides in malignant cells
    $455,216.00 [Total Cost]
    Co-Investigator

Selected Awards:

  • Chancellor's Distinguished Research Award, Texas Tech University System, 2019.
  • Outstanding Faculty Award, Student Government Association (SGA), 2016.
  • President's University Distinguished Professor Award, Texas Tech University Health Sciences Center, 2015.
  • Oustanding Faculty Award, TTUHSC Student Government Association (SGA), 2014.
  • President's Excellence in Research Award, Texas Tech University Health Sciences Center, 2013.

Selected Scheduled Teaching:

  • GBCM6320 Advanced Cell Biology - Spring 2019
  • GBTC5340 Biology of Cancer - Spring 2019
  • GSBS5372 Core II: Cells - Fall 2018
  • GMED GPMDC Medical Pharmacology - Fall 2018
  • GSBS5098 Techniques in Biomedical Research - Summer 2018

Selected Directed Student Learning:

  • Dissertation Committee Member 2017 - Present
  • Dissertation Committee Member 2015 - Present
  • Dissertation Committee Member 2015 - Present
  • Dissertation Committee Member 2015 - Present
  • Dissertation Committee Chair 2014 - Present

Selected Non-Credit Instruction Taught:

  • Small Group Conferences - TTU Lambda Delta Psi Student Association, October 2018 - October 2018
  • Small Group Conferences - Texas Tech University, Lubbock, Texas, TTU Lambda Delta Psi's Event, October 2017
  • Seminar - Texas Tech University Health Sciences Center, Translational Research Seminar, Acute Lymphoblastic Leukemia: Drug Development, November 2015
  • Invited presentations - 3. Advances in Neuroblastoma Research Conference 2010, Stockholm, Sweden. , Fenretinide (4-HPR) orally formulated in Lym-X-SorbTM(LXS) lipid matrix or as an intravenous emulsion increased 4-HPR systemic exposure in patients with Recurrent or Resistant Neuroblastoma. A new approaches to neuroblastoma therapy (NANT) consortium trial , June 2010 - June 2010
  • Invited presentations - Seminar at National Cancer Institute. May 20th, 2010, Bethesda, MD, Overcoming drug resistance in pediatric acute lymphoblastic leukemia, May 2010 - May 2010
Research Interests

Pediatric Cancers (leukemia and neuroblastoma)
Small Cell Lung Caner
Drug resistance mechanisms
Molecular mechanisms of c-MYC activation
Drug discovery and development
Pharmacology and pharmacokinetics

Teaching Interests

Cancer Biology, Clinical and Medical Pharmacology

Links

Date last updated: 10/16/2019